<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03205618</url>
  </required_header>
  <id_info>
    <org_study_id>AI444-382</org_study_id>
    <nct_id>NCT03205618</nct_id>
  </id_info>
  <brief_title>A Retrospective, Observational Study on the Effectiveness of Daclatasvir-Containing Regimens in Patients in KSA, UAE and Qatar</brief_title>
  <official_title>Effectiveness of Daclatasvir-Containing Regimens in Patients Treated in Real-Life Setting in Kingdom of Saudi Arabia (KSA), United Arab Emirates (UAE) and Qatar</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will provide safety and efficacy information among patients receiving daclatasvir.
      It will describe daclatasvir prescribing patterns and provide a clinical profile of patients
      receiving the treatment in KSA, UAE, and Qatar.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 26, 2016</start_date>
  <completion_date type="Actual">June 27, 2017</completion_date>
  <primary_completion_date type="Actual">June 27, 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants achieving sustained virological response 12 weeks post-treatment (SVR12)</measure>
    <time_frame>12 weeks after the last dose of study treatment</time_frame>
    <description>Patients will be considered to have achieved SVR12 if they have a documented undetectable viral load on or after Week 12 following the end of treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Distribution of SVR12 by Treatment Regimen</measure>
    <time_frame>12 weeks after the last dose of study treatment</time_frame>
    <description>Defined as any daclatasvir containing regimen. Subgroups include: daclatasvir + sofosbuvir; daclatasvir + sofosbuvir + RBV; daclatasvir + simeprevir; daclatasvir + simeprevir + ribavirin.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distribution of SVR12 by Country</measure>
    <time_frame>12 weeks after the last dose of study treatment</time_frame>
    <description>Defined as the country where treatment with a daclatasvir containing regimen was initiated. Subgroups include Saudi Arabia, UAE, and Qatar.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distribution of SVR12 by Genotype</measure>
    <time_frame>12 weeks after the last dose of study treatment</time_frame>
    <description>Subgroups genotype 3 and genotype 4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distribution of SVR12 by HCV-Treatment Experience</measure>
    <time_frame>12 weeks after the last dose of study treatment</time_frame>
    <description>Subgroups include patients in which prior treatment with IFN and RBV has failed; prior treatment with IFN, RBV and telaprevir or boceprevir has failed; previous treatment with IFN, RBV and simeprevir has failed; previous treatment with sofosbuvir and RBV has failed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distribution of SVR12 by HIV co-infection</measure>
    <time_frame>12 weeks after the last dose of study treatment</time_frame>
    <description>Subgroup defined as HIV diagnosis prior to the initiation of daclatasvir containing regimen.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distribution of SVR12 by previous liver transplantation</measure>
    <time_frame>12 weeks after the last dose of study treatment</time_frame>
    <description>Subgroup defined by patients undergoing a liver transplant for any cause prior to the initiation of a daclatasvir containing regimen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Serious Adverse Events (SAE)</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Measured by number of patients reporting SAEs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse Events leading to discontinuation</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Measured by number of patients reporting AEs that result in treatment discontinuation</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">182</enrollment>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>daclatasvir patients in KSA, UAE, and Qatar</arm_group_label>
    <description>patients treated with daclatasvir-containing regimens in KSA, UAE, and Qatar</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Non-Interventional</intervention_name>
    <description>Non-Interventional</description>
    <arm_group_label>daclatasvir patients in KSA, UAE, and Qatar</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The study will enroll all patients initiating a new daclatasvir-containing HCV treatment,
        regardless of treatment history and previous treatment response from availability of the
        drug on country markets up to 01-Oct-2015.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients greater than or equal to 18 years of age

          -  Diagnosed with chronic hepatitis C

          -  Ended treatment with daclatasvir-containing regimen no later than 01-Oct-2015

        Exclusion Criteria:

          -  Use of a daclatasvir-containing regimen in a clinical trial setting

        Other protocol defined inclusion/exclusion criteria could apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Doha</city>
        <country>Saudi Arabia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Jeddah</city>
        <zip>23325</zip>
        <country>Saudi Arabia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Riyadh-11211</city>
        <zip>11211</zip>
        <country>Saudi Arabia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Saudi Arabia</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_inquiry_form.aspx</url>
    <description>Investigator Inquiry Form</description>
  </link>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 29, 2017</study_first_submitted>
  <study_first_submitted_qc>June 29, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 2, 2017</study_first_posted>
  <last_update_submitted>October 10, 2017</last_update_submitted>
  <last_update_submitted_qc>October 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis C</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

